플러스100%마이너스

  • 화면크기
통합검색

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Electroacupuncture plus on-demand gastrocaine for refractory functional dyspepsia: Pragmatic randomized trial.

Authors

Chung VC, Wong CH, Wu IX, Ching JY, Cheung WK, Yip BH, Chan KL, Cheong PK, Wu JC.

Journal

J Gastroenterol Hepatol.

Year

2019

Vol (Issue)

34(12)

Page

2077-85.

doi

101111/jgh14737.

PMID

31117149

Url

http://www.ncbi.nlm.nih.gov/pubmed/31117149

MeSH

Adult
Aluminum Hydroxide / administration & dosage
Aluminum Hydroxide / therapeutic use*
Aminobenzoates / administration & dosage
Aminobenzoates / therapeutic use*
Atropine / administration & dosage
Atropine / therapeutic use*
Combined Modality Therapy
Drug Administration Schedule
Drug Combinations
Dyspepsia / drug therapy*
Electroacupuncture / adverse effects
Electroacupuncture / methods*
Female
Humans
Magnesium Compounds / administration & dosage
Magnesium Compounds / therapeutic use*
Male
Middle Aged
Prospective Studies
Single-Blind Method
Treatment Outcome

Keywords

acupuncture; functional dyspepsia; on-demand antacid; randomized trial

한글 키워드

침 치료; 기능성 소화불량; 대기대조군; 무작위배정 임상시험

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

Background and aim: Treatment options for functional dyspepsia (FD) refractory to pharmacological treatments are limited but the effectiveness of electroacupuncture (EA) is uncertain. We assessed the effectiveness of EA combined with on-demand gastrocaine.

Methods: We conducted a single-center, assessor-blind, randomized parallel-group 2-arm trial on Helicobacter pylori negative FD patients of the postprandial distress syndrome subtype refractory to proton pump inhibitor, prokinetics, or H2 antagonists. Enrolled participants were block randomized in a 1:1 ratio, with concealed random sequence. The treatment and control groups both received on-demand gastrocaine for 12 weeks, but only those in treatment group were offered 20 sessions of EA over 10 weeks. The primary endpoint was the between-group difference in proportion of patients achieving adequate relief of symptoms at week 12.

Results: Of 132 participants randomly assigned to EA plus on-demand gastrocaine (n = 66) or on-demand gastrocaine alone (n = 66), 125 (94.7%) completed all follow-up at 12 weeks. The EA group had a compliance rate 97.7%. They had a significantly higher likelihood in achieving adequate symptom relief at 12 weeks, with a clinically relevant number needed to treat (NNT) value of 2.36 (95% CI: 1.74, 3.64). Among secondary outcomes, statistically and clinically significant improvements were observed among global symptom (NNT = 3.85 [95% CI: 2.63, 7.69]); postprandial fullness and early satiation (NNT = 5.00 [95% CI: 2.86, 25.00]); as well as epigastric pain, epigastric burning, and postprandial nausea (NNT = 4.17 [95% CI: 2.56, 11.11]). Adverse events were minimal and nonsignificant.

Conclusion: For refractory FD, EA provides significant, clinically relevant symptom relief when added to on-demand gastrocaine (ChiCTR-IPC-15007109).

국문초록

Language

영어

첨부파일